Baysient to Release iDose Software Technology Platform 1.0 to Reduce the Biosimilar Cost in Market

• The 12-month clinical validation study (NCT02453776) data demonstrated the reduction “switching” from lower cost infliximab to more expensive biologics by 66%. Also, similar studies are ongoing in 9 countries on 3 continents
• The results were already presented at ECCO, Copenhagen, Mar 2019 and DDW, San Diego, May 2019 and the Baysient pipeline includes CDS for 25 FDA approved anti-inflammatory biologics. The HCPs using iDose software’s CDS reduced the cost $726,000 per 100 patients
• The iDose algorithm is a cloud base SaaS and is HIPAA-compliant, compatible with EMRs offered in the US and Canada, combines the PK data with Bayesian learning (non-AI machine learning) and forecasting, also enables the physicians to understand how to keep the amount of drug in patient’s body from falling below the physician-selected target

Click here to read full press release/ article | Ref: PR Newswire | Image: Behance